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After their initial encounter with T cell–dependent antigens, 
B cells migrate to the interface between the T and B cell 
zones in lymphoid organs, where they interact with cognate 
T cells to form antigen-specific cell clusters. After leaving these 
clusters, B cells undergo brisk proliferation before entering 
the GC reaction or developing into short-lived plasmablasts 
(herein called the preGC period; Victora and Mesin, 2014; De 
Silva and Klein, 2015).
Once a GC is established in the B cell follicle, the dark 
zone (DZ) and light zone (LZ) form and the GC B cells 
then cycle between them (Allen et al., 2007; Victora and Nus-
senzweig, 2012). B cells in these two zones can be identified 
based on expression levels of the signature surface proteins 
CXCR4, CD83, and CD86; DZ GC cells express higher lev-
els of CXCR4, but lower levels of CD83 and CD86, whereas 
LZ cells are CXCR4low, CD83hi, and CD86hi. Proliferation 
and somatic hypermutation (SHM) occur in the DZ, and 
then the B cells shuttle to the LZ, where they exit the cell 
cycle. In the LZ, de novo mutated BCRs capture antigen and 
internalize it for MHC class II (MHC-II) presentation to fol-
licular helper T (TFH) cells. According to the current model 
(Allen et al., 2007; Victora et al., 2010; Liu et al., 2015), GC 
B cells expressing high-affinity BCRs are selected in response 
to signals provided by cognate TFH cells in the LZ. Next, as 
cells transit from the LZ back to the DZ, proliferation is in-
duced. Therefore, it has been argued that induction of pro-
liferation after receipt of TFH cell help is well coupled to the 
LZ-to-DZ transition. Ultimately, after several such iterative 
cycles of proliferation, diversification, and selection, the GC 
generates high-affinity plasma cells and memory B cells.
In regard to the molecular processes for DZ cyclic reen-
try, it has been demonstrated that c-Myc plays an important 
role because it is expressed by a small fraction of LZ GC 
B cells that are enriched for high-affinity BCRs and have 
recently entered the S phase of the cell cycle (Calado et 
al., 2012; Dominguez-Sola et al., 2012; Gitlin et al., 2015). 
Transient c-Myc expression can be induced by forcing T–B 
cell interactions, leading to reentry into the DZ and stimu-
lation of cell division.
Recently, the role of Foxo1 in the transition from the 
LZ-to-DZ program has been explored by two studies, both 
indicating that this transcription factor plays a regulatory role 
in the formation and maintenance of the GC DZ, as in its 
absence there was no DZ in the GC (Dominguez-Sola et 
al., 2015; Sander et al., 2015). Notably, in these studies the 
overall GC size was intact even in the absence of Foxo1, a 
finding somewhat at odds with the aforementioned cou-
pling model between proliferation and the LZ-to-DZ tran-
sition. Because the chemokine receptor CXCR4 is one of 
the direct physiological Foxo1 targets (Dubrovska et al., 2012; 
Dominguez-Sola et al., 2015), the observed DZ defect in 
Foxo1-deficient GC B cells has been explained, at least in 
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part, by down-regulation of CXCR4. However, function-
ally, the Foxo1-deficient GC B cells appear to be more se-
verely affected than in the CXCR4 knockout (Bannard et al., 
2013). For instance, down-regulation of CD86 occurred in 
both Cxcr4−/− and wild-type GC B cells, whereas this regula-
tion was perturbed in Foxo1-deficient GC B cells. These data 
imply that the loss of CXCR4 expression is necessary but not 
sufficient to account for the defective DZ program resulting 
from Foxo1 ablation, prompting us to investigate how Foxo1 
participates in the transition from the LZ to the DZ program.
Here, we report that, in addition to CXCR4, Foxo1 
participates in up-regulation of the transcription factor BATF. 
BATF was transiently expressed in a small fraction of LZ GC 
cells, and depletion of BATF, like that of Foxo1, led to the GC 
disruption. Hence, our results suggest that Foxo1 controls not 
only GC polarization, but also GC proliferation, at least in 
part, through mediating BATF expression, together contrib-
uting to the transition from the LZ to DZ program.
resuLts
Hyperexpansion of preGc B cells after Foxo1 ablation
To examine the effects of Foxo1 ablation on antigen-driven 
clonal expansion and GC differentiation, we used adoptive 
transfer experiments using B1-8hi BCR heavy chain knock-in 
B cells, which are specific for the hapten 4-hydroxy-3-nitro-
phenylacetyl (NP) when combined with Igλ light chains. Be-
fore examining the B cell intrinsic biological roles of Foxo1, 
we analyzed Foxo1 expression during an immune response. 
B1-8hi B cells were transferred into congenically marked 
mice and immunized with NP-chicken γ globulin (CGG)/
alum. Foxo1 protein expression level, assessed by intracellular 
flow cytometry, was similar or slightly higher in proliferative 
CD38+GL7− or CD38+GL7+ B cells than in their naive B 
cell counterparts (Fig. 1 A). Compared with parental naive 
B cells, the Foxo1 expression level in LZ GC B cells was 
higher and the expression level in the DZ GC B cells was 
higher than that in LZ GC B cells (Fig. 1 A). This differential 
Foxo1 expression between the DZ and LZ GC B cells was 
confirmed by Western blot and was also apparent in Foxo1 
mRNA levels (Fig. 1 B).
To examine the role of Foxo1 in expansion of preGC 
B cells, we co-transferred equal numbers of Foxo1f/f ERT2cre 
B1-8hi and Foxo1+/+ ERT2cre B1-8hi B cells into con-
genically marked mice, which were then immunized with 
NP-CGG/alum after tamoxifen treatment (Fig. 1 C). In this 
protocol, deletion of Foxo1 was very efficient (Fig.  1  D), 
and did not result in any induction of Foxo3 or Foxo4 
mRNA (not depicted). Expansion of preGC B1-8hi B cells 
(GL7+CD38+IgD+CCR6hi) and their subsequent differenti-
ation toward early GC B cells (IgDloCCR6lo; Schwickert et 
al., 2011) were enhanced when Foxo1 was eliminated; con-
trol vehicle treatment had essentially no effects. These obser-
vations appear to be consistent with the conventional view 
that Foxo family transcription factors act as tumor suppressors 
(Dansen and Burgering, 2008; Hedrick, 2009).
Gc maintenance requires Foxo1
The idea that Foxo1 might play a proliferative, rather than 
antiproliferative, role during the GC phase has been suggested 
by an earlier study showing that GC-derived lymphomas fre-
quently carry mutations in Foxo1 that prevent its inactivation 
by Akt (Trinh et al., 2013). Hence, we wished to delete Foxo1 
specifically during the GC stage. To do this, we used the same 
co-transfer experiments as Fig. 1 C, but used the time course 
depicted in Fig. 2 A, because almost all the transferred B1-8hi 
B cells in our experimental conditions were already differen-
tiated into GC B cells by day 7. If tamoxifen was administered 
at earlier time points, for instance at day 4, deletion of Foxo1 
would occur at both preGC and GC stages, possibly compli-
cating interpretation of the data.
Tamoxifen injection resulted in selective diminution of 
Foxo1f/f ERT2cre B1-8hi GC B cells; both IgG1− and IgG1+ 
B1-8hi GC B cells were similarly affected by Foxo1 abla-
tion, whereas control vehicle treatment had no effect (Fig. 2, 
B and C). In this protocol, Foxo1 protein and mRNA were 
efficiently depleted in GC B cells (labeled as Foxo1f/f in 
Fig. 1 B). The similar loss of IgG1− and IgG1+ GC B cells 
indicates that deletion of Foxo1 takes place after comple-
tion of class switch recombination (CSR) in our protocol, 
being different from the previous two studies by using a 
Cγ1-cre (Dominguez-Sola et al., 2015; Sander et al., 2015); 
indeed, previous studies demonstrate the involvement of 
Foxo1 in CSR processes.
To further examine whether Foxo1 ablation affects cell 
division, we compared the frequency of Foxo1-deficient and 
-proficient LZ GC B cells in the S–G2–M phase of the cell 
cycle. By DNA content measurement, Foxo1-deficient LZ 
GC B cells exhibited less proliferation status than control cells 
(Fig.  2 D, left), and a similar result was obtained when in-
corporation of the nucleotide analogue 5-ethynyl-2’-deoxy-
uridine (EdU) over a 0.5-h period was compared (Fig. 2 D, 
right). Hence, we conclude that Foxo1 ablation in GC cells 
decelerates cell cycle progression.
We then examined the effects of Foxo1 deletion on DZ/
LZ compartmentalization. Consistent with previous studies 
(Dominguez-Sola et al., 2015; Sander et al., 2015), the majority 
of the Foxo1-deficient GC B cells were CXCR4lowCD86hi, 
reminiscent of LZ cells, although a DZ-like population 
(CXCR4int) was to some extent detectable, particularly among 
IgG1− cells (Fig. 2 B). The compartmentalization defect was 
also confirmed histologically. To do this, we also used co-transfer 
experiments (Fig. 2 E). In contrast to control vehicle treatment, 
localization of tamoxifen-treated Foxo1f/f ERT2cre B1-8hi GC 
cells was largely restricted to the LZ, which was defined by the 
presence of the CD35+ follicular dendritic cell (FDC) network. 
These results suggest that Foxo1-deficient cells are locked in 
the LZ even in a GC where overall DZ/LZ compartmentaliza-
tion is preserved. Together, deletion of Foxo1 in the GC phase 
resulted in GC disruption and defective polarization.
The loss of the DZ compartment in Foxo1-deficient 
GC cells was further substantiated by gene expression pro-
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Figure 1. Hyperexpansion of preGc B cells with Foxo1 ablation. (A) Left, flow cytometry of intracellular Foxo1 protein expression in naive B cells 
at day 0 (CD45.1+B220+NP+CD38+), activated B cells on day 4 (CD45.1+B220+NP+CD38+GL7− or CD45.1+B220+NP+CD38+GL7+), LZ (CD45.1+B220+N-
P+CD38−CD86hiCXCR4lo), and DZ (CD45.1+B220+NP+CD38−CD86loCXCR4hi) GC B cells on day 10. Wild-type mice were transferred with B1-8hi CD45.1+ 
B cells and then immunized i.p. with NP-CGG/alum on day 0. Foxo1 KO staining controls (gray histograms) were prepared as previously described in Figs. 
1 C and 2 A. (right) Histograms indicating the geometric mean fluorescence intensity (gMFI) of each population. n = 4 biological replicates. (B) Analysis of 
Foxo1 protein and mRNA expression in DZ and LZ GC B cells by Western blot (top) and real-time qPCR (bottom). Foxo1-proficient LZ, DZ, and Foxo1-defi-
cient GC B cells were sorted from mice prepared as described in Fig. 2 A. Actin, loading control. n = 3 biological replicates. (C, top) Schematic illustration of 
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file analysis. We prepared mRNA from Foxo1+/+ ERT2cre 
B1-8hi DZ and LZ GC B cells and from Foxo1f/f ERT2cre 
B1-8hi total GC B cells after tamoxifen treatment at day 12 
(Fig. 2 A), and performed transcriptome analysis by RNA-
seq. A hierarchical clustering analysis indicated that the 
Foxo1-deficient GC B cells are more similar to normal LZ 
than DZ B cells; the mutant GC profile exhibited a signifi-
cant absence of gene signatures associated with the DZ pro-
gram (Fig. 2 F). Hence, our results demonstrate that Foxo1 
directly or indirectly controls a major part of the program that 
distinguishes DZ from LZ GC B cells. However, when com-
pared with normal LZ GC B cells, some differences were also 
noted in the Foxo1-deficient GC B cells. Indeed, gene set 
enrichment analysis (Foxo1-deficient GC B cells versus con-
trol LZ GC B cells) indicated that the Foxo1-deficient cells 
were more weakly imprinted with the signatures of CD40 
and BCR signaling (Fig. 2 G).
When Foxo1+/+ ERT2cre B1-8hi and Foxo1f/f ERT2cre 
B1-8hi B cells were individually transferred (Fig. 3 A), instead 
of co-transferred, the similar compartmentalization defect 
was observed (Fig. 3 B). The proliferation defect was also ob-
served in the individual transfer experiments, but the defective 
extent in the absence of Foxo1 was relatively small, compared 
with co-transfer experiments (Fig. 3, C and D). Hence, we 
conclude that Foxo1 deletion directly causes the proliferative 
changes, although, in the aforementioned mixed B cell chi-
mera experimental settings, cell competition takes place.
Our conclusion that the number of Foxo1-deficient GC 
B cells is decreased differs from previous studies demonstrat-
ing that the GC size is unchanged in the absence of Foxo1 
(Dominguez-Sola et al., 2015; Sander et al., 2015). As these 
studies analyzed polyclonal GC responses, we reasoned that 
the polyclonal versus our monoclonal system might cause 
such differences. To test this possibility, we co-transferred 
equal numbers of Foxo1f/f ERT2cre and Foxo1+/+ ERT2cre 
donor B cells into congenically marked mice and immunized 
them with sheep RBCs (SRBCs). Foxo1 was then deleted 
as depicted in Fig. 4 A and, overall, both GC maintenance 
and GC compartmentalization were decreased by the loss of 
Foxo1 (Fig.  4  B). However, compared with the aforemen-
tioned results using B1-8hi B cells, the decrease in polyclonal 
Foxo1-deficient GC B cell numbers was relatively small. 
Given the hyperexpansion of B cells caused by deletion of 
Foxo1 at the preGC stage, one possibility is that, because of 
the asynchrony of the polyclonal immune responses, some ac-
tivated B cells might still have been at the preGC stage when 
Foxo1 was deleted (Fig. 4 A), thereby diluting the effects by 
GC-specific deletion of Foxo1. It is also possible that mono-
clonal BCR transgenic B cells might enhance the activation 
kinetics, which in turn makes more differences particularly in 
the competitive settings.
Antigen presentation is inhibited
As GC B cell proliferation is only marginally affected in 
Cxcr4−/− mice (Bannard et al., 2013), the aforementioned 
findings suggest that, in addition to regulating access into the 
anatomical DZ, Foxo1 utilizes other mechanisms, thereby 
regulating the transition from the LZ-to-DZ program. Ac-
cording to the current model (Allen et al., 2007; Victora et 
al., 2010; Liu et al., 2015), the LZ-to-DZ transition is thought 
to be regulated by two consecutive processes; first, the BCR 
on LZ B cells functions as an endocytic receptor that shuttles 
antigen into the MHC-II pathway for processing and pre-
sentation to TFH cells; second, the antigen-specific TFH cells 
activated by cognate interaction with the LZ B cells in turn 
provide them with T cell help, driving their transition to the 
DZ program. Hence, we reasoned that Foxo1 might partici-
pate in these two processes.
Before addressing whether the first processes are af-
fected by Foxo1 ablation, we analyzed receptors relevant to 
this process and found that expression of BCR and Igβ in 
Foxo1-deficient GC cells was lower compared with control 
cells (Fig.  5 A). Then, to examine the antigen presentation 
activity on GC B cells to TFH cells, we generated a chemi-
cal conjugate of NP and recombinant Eα-GFP, which con-
tains the Eα peptide from the I-E molecule (pEα) fused GFP 
(Pape et al., 2007). This reagent allows for quantification of 
the amount of peptide MHC class II (pMHC-II) presenta-
tion. The pMHC-II can be monitored with the Y-Ae mono-
clonal antibody, which is specific for pEα–I-Ab complexes 
(Murphy et al., 1992).
Although we detected antigen capture and pMHC-II 
on activated B1-8hi B cells at the preGC stage after NP-Eα-
GFP/alum immunization, neither could be detected on GC 
B cells (unpublished data). The most likely explanation for 
this is that the antigen availability in the microenvironments 
of the GC is very limited, thereby making it undetectable in 
vivo by our experimental system. Therefore, in the case of 
GC B cells, we performed ex vivo experiments. As shown in 
Fig. 5 B, when antigen was provided, Foxo1-deficient B1-8hi 
LZ GC B cells were able to present pMHC-II lesser extent 
than control cells; both population of pMHC-II+ cells and 
their expression levels were low. Next, to ask the question of 
why mutant GC B cells possess the low antigen presentation 
activity, we delivered the Eα-GFP antigen to GC B cells in a 
surrogate manner. For this purpose, instead of targeting to the 
the experimental protocol. (bottom left) Flow cytometry of NP-specific donor B cells (CD45.1+B220+NP+). (bottom right) Histograms representing the cell 
number of preGC (Donor B220+NP+GL7+CD38+IgD+CCR6hi) and early GC (Donor B220+NP+IgDloCCR6lo) B cells in 106 splenocytes. n = 3 biological replicates. 
(D) Real-time qPCR analysis of Foxo1 mRNA expression in Foxo1+/+ERT2cre B1-8hi and Foxo1f/f ERT2cre B1-8hi preGC B cells. Error bars represent SD. Data 
are representative of three (A) or two (B and C) independent experiments, and from one experiment with three biological replicates (D). *, P < 0.05; **, P < 
0.01; ***, P < 0.001; unpaired Student’s t test (A, B, and D) and paired Student’s t test (C).
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Figure 2. Foxo1 is required for Gc maintenance. (A) Schematic illustration of the experimental protocol for B–D, F, and G. (B) Flow cytometry of 
NP-specific donor B cells (CD45.1+B220+NP+). (C) Histograms representing the number of donor IgG1− GC B cells (CD45.1+B220+NP+CD38−IgG1−) and IgG1+ 
GC B cells (CD45.1+B220+NP+CD38−IgG1+) in 106 splenocytes (left), and the ratio of DZ:LZ cells (right). n = 3 biological replicates. (D, left) DNA content 
measurement of Foxo1+/+ and Foxo1f/f LZ GC B cells assessed by 7-AAD staining. n = 5 and 3 biological replicates for tamoxifen and vehicle treatment, 
respectively. (right) Proliferation status of Foxo1+/+ and Foxo1f/f LZ GC B cells assessed by EdU incorporation 30 min after an EdU injection. n = 3 biological 
replicates. (E) Immunohistochemical analysis. (top) Schematic illustration of the experimental protocol. (bottom left) Representative images of immunofluo-
rescence microscopy of spleen sections showing expression of CD45.1 (Foxo1f/f-derived donor cells), CD35 (FDC network), and IgD (follicular B cells). DZ and 
LZ defined by the presence of CD35+ FDCs are surrounded by dashed lines. Bars, 100 µm. (bottom right) Quantification of relative CD45.1 signal intensity 
 o
n






Regulation of GC B cell proliferation by Foxo1 | Inoue et al.6
BCR, we used DEC205. DEC205 is a cell surface receptor, 
which was expressed to similar extents between wild-type and 
Foxo1-deficient LZ GC B cells (unpublished data). Eα-GFP 
was fused to an antibody specific to DEC205 (anti–DEC-
Eα-GFP). Upon provision of anti–DEC-Eα-GFP, control 
and Foxo1-deficient B1-8hi LZ GC B cells showed similar 
presentation of the pMHC-II complex on the cell surface 
(Fig. 5 C), indicating that the antigen presentation machinery, 
itself, operates similarly in control and Foxo1-deficient GC 
B cells. Collectively, the defective antigen presentation activ-
ity in Foxo1-deficient GC B cells is most likely explained by 
the low level of BCR expression on them.
Because CD19 is known to act as a BCR co-recep-
tor, we wondered whether the decreased CD19 expression 
(Fig. 5 A) might affect antigen presentation activity. To ex-
amine this possibility, we immunized Cd19cre/+ mice, because 
Cd19cre/+ mice retain only one functional Cd19 allele (Rick-
ert et al., 1997). The ex vivo antigen presentation activity of 
the LZ GC B cells was unchanged by haploinsufficiency of 
CD19 (unpublished data).
Because activation of GC TFH cells requires pMHC-II 
on LZ GC B cells, the aforementioned observations predict 
that ablation of Foxo1 in GC B cells would render the GC 
TFH cells less active in vivo. To test this prediction, after trans-
ferring OVA-specific TCR transgenic (OT-II) CD4+ T cells 
together with Foxo1f/f ERT2cre B1-8hi or Foxo1+/+ ERT2cre 
B1-8hi B cells, we immunized the mice with NP-OVA and 
deleted Foxo1 as depicted in Fig. 5 D. 3 d after Foxo1 abla-
tion in GC B cells, both the GC TFH cell numbers and pro-
duction of IL-21 were decreased. These results suggest that 
Foxo1 contributes to antigen presentation by GC B cells and, 
subsequently, to activation of GC TFH cells.
In addition to this defective antigen presentation 
on Foxo1-deficient LZ GC B cells, the lower expression 
of CD86 in the mutant cells, albeit being a small change 
(Fig.  5  A), might also be involved in subsequent defective 
activation of GC TFH cells.
upon access to t cell help, Foxo1-deficient Gc cells 
have a proliferation defect
We then specifically examined the second process, namely 
Foxo1 involvement in the transition from the LZ to the DZ 
state after receipt of T cell help. To address this issue, we 
adopted an in vivo approach to enforce T cell–B cell interac-
tions by using a T cell antigen (OVA) fused to anti-DEC205 
antibody (anti–DEC-OVA; Bonifaz et al., 2002). As shown 
in Fig.  6  A, after co-transferring of Foxo1+/+ ERT2cre 
B1-8hi and Foxo1f/f ERT2cre B1-8hi B cells, the recipient 
mice were immunized with NP-OVA. When stimulated with 
anti-DEC-OVA after tamoxifen treatment, Foxo1+/+ but not 
Foxo1-deficient GC B cells showed a burst of proliferation; 
control vehicle treatment did not induce such differential re-
sponses. Thus, we conclude that, even after they receive suf-
ficient T cell help, Foxo1-defcient GC B cells cannot induce 
the normal proliferation program.
Consistently, the mutation load in a 570 bp intronic re-
gion downstream of JH4 exon of the Igh locus was lower 
in the Foxo1-deficient LZ GC B cells compared with the 
controls (Fig. 6 B). Therefore, efficient SHM requires Foxo1. 
Polh, Lig4, Dnase1, and Aicda genes are involved in SHM and 
their transcripts are abundant in the DZ B cells (Victora et 
al., 2012). Compared with Foxo1-proficient LZ GC B cells, 
all had higher mRNA expression levels in Foxo1-deficient 
GC B cells, whereas their levels did not reach those in wild-
type DZ GC B cells, except Aicda (Fig. 6 C, left). Despite 
the similar mRNA levels of Aicda between Foxo1-deficient 
GC B cells and Foxo1-proficient DZ GC B cells, its protein 
expression in the mutant cells did not reach that in wild-
type DZ GC B cells (Fig.  6  C, right). Thus, key enzymes 
involved in SHM were up-regulated, to some extents, even 
in the absence of Foxo1, but not corresponding to the level 
in wild-type DZ GC cells.
t cell help triggers BAtF in a Foxo1-dependent manner  
and is required for Gc maintenance
Having demonstrated the importance of Foxo1 in regulating 
the GC B cell proliferation program upon receipt of T cell 
help, we wished to address how Foxo1 exerts this function. 
To do this, we first examined the expression of CD40 and 
IL-21R, critical receptors for receiving T cell help (Victora 
and Nussenzweig, 2012), on Foxo1-deficient B1-8hi LZ GC 
B cells. Expression of CD40 was similar, but that of IL-21R 
was somewhat lower in Foxo1-deficient LZ GC B cells com-
pared with control cells (Fig. 5 A). To examine whether the 
decreased expression of IL-21R affects the proliferation pro-
gram of GC B cells, we generated bone marrow chimeras 
that lack IL-21R on B cells by reconstituting mice with a 
mixture of bone marrow cells from μMT and Il21r+/− mice, 
and immunized them with NP-CGG/alum. Despite two-
fold lower expression of IL-21R on Il21r+/− LZ GC B cells, 
the number of GC B cells was unaffected (unpublished data). 
Moreover, IL-21R expression by Foxo1-deficient LZ GC 
B cells was higher than that of IL-21R haploinsufficient cells 
(unpublished data). Thus, the expression level of key receptors 
in the DZ compared with that in the LZ. Each symbol represents a single GC, and red bars indicate the mean. n = 43 (tamoxifen) and 40 (vehicle) GC pooled 
from three animals. (F) Hierarchical clustering of the gene expression profiles of Foxo1+/+ DZ, Foxo1f/f GC, and Foxo1+/+ LZ B cells using genes differentially 
expressed (more than twofold) between Foxo1+/+ DZ and Foxo1+/+ LZ B cells (normalized log2 values based on RNA-seq analysis). n = 3 biological replicates. 
(G) Gene set enrichment analysis showing the enrichment for genes up-regulated after ligation of CD40 (top) and BCR (bottom) compared of Foxo1+/+ LZ 
B cells with Foxo1f/f GC B cells. Error bars represent SD. Data are representative of three (B and C) or two independent experiments (D and E) and from one 
experiment (F and G). **, P < 0.01; ***, P < 0.001; unpaired Student’s t test (E) and paired Student’s t test (C and D).
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for receiving T cell help appears not to be solely responsible 
for the defective proliferation in Foxo1-deficient GC B cells.
Previous studies have shown that transient c-Myc expres-
sion only in the LZ is induced by forcing T–B cell interac-
tions and is required for stimulating cell division (Calado et 
al., 2012; Dominguez-Sola et al., 2012). We thus hypothesized 
that such cell division-related key transcription factors might 
exist in the LZ GC B cells, induced by T cell help in a Foxo1- 
dependent manner. Among transcription factors differentially 
expressed between LZ and DZ GC B cells (Victora et al., 2012), 
c-Myc, Egr2, Egr3, BATF, and Foxp1 were significantly down- 
regulated and Lmo2 was up-regulated in Foxo1-deficient 
B1-8hi GC B cells (Fig. 7 A). A previous study demonstrated that 
transgenic expression of FoxP1 leads to a significant decrease in 
GC B cells (Sagardoy et al., 2013). In addition, Egr2 and Egr3 
have been shown to be negative regulators of T cell activation 
(Safford et al., 2005; Zheng et al., 2012), and Lmo2 has been 
suggested as a proto-oncogene in T cell acute lymphoblastic 
leukemia and in other type of cancers (Chambers and Rabbitts, 
2015). Based on these observations, involvement of Egr2, Egr3, 
Foxp1, and Lmo2 in GC proliferation in a Foxo1-dependent 
manner appeared to be somewhat unlikely. Because c-Myc was 
already well characterized (Calado et al., 2012; Dominguez-Sola 
et al., 2012), we focused our analysis here on BATF.
Figure 3. Assessment of Foxo1 requirement 
for Gc maintenance and proliferation in single 
transfer experiments. (A) Schematic illustration of 
the experimental protocol. (B) Flow cytometry of NP- 
specific donor B cells (CD45.1+B220+NP+). (C) His-
tograms representing the number of donor IgG1− 
GC B cells (CD45.1+B220+NP+CD38−IgG1−) and IgG1+ 
GC B cells (CD45.1+B220+NP+CD38−IgG1+) in 106 sple-
nocytes (left), and the ratio of DZ:LZ cells (right). n = 5 
biological replicates. (D) Proliferation status of 
Foxo1+/+ and Foxo1f/f LZ GC B cells assessed by EdU 
incorporation 30 min after an EdU injection. n = 3 bio-
logical replicates. (E) Analysis of Batf mRNA expression 
in Foxo1+/+ DZ, LZ, and Foxo1f/f GC B cells by real-time 
qPCR. n = 3 biological replicates. Error bars repre-
sent SD. Data are representative of three (B and C) or 
two independent experiments (D and E). **, P < 0.01; 
***, P < 0.001; unpaired Student’s t test.
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Indeed, provision of in vivo T cell help by injection 
of anti–DEC-OVA induced up-regulation of Batf mRNA 
in B1-8hi GC LZ B cells, and this was dependent on Foxo1 
(Figs. 3 E and 7 B). Conversely, inhibition of the T-B inter-
actions in vivo by CD40 blockade decreased Batf expression 
(Fig. 7 C). Next, we wondered whether BATF, like c-Myc, 
is dominantly expressed in a small fraction of LZ GC B cells 
and, if so, whether this small BATFhi LZ fraction is more 
actively cycling than the BATFlo LZ cells. After NP-CGG 
immunization of wild-type mice, BATFhi and BATFlo frac-
tions were present among the LZ GC B cells, as assessed by 
intracellular cytometry analysis (Fig. 7 D), and the population 
of the BATFhi fraction was increased by anti–DEC-OVA in-
jection (Fig. 7 D). Moreover, the BATFhi cells were more ac-
tively cycling (Fig. 7 E). To examine the relationship between 
BATFhi cells and c-Myc+ cells in the LZ, we used NP-CGG– 
immunized mice harboring c-Myc-GFP (Huang et al., 2008). 
According to these staining patterns, c-Myc+ cells were 
mainly included in the BATFhi LZ fraction; ∼30% among 
BATFhi cells coexpressed c-Myc (Fig. 7 F). BATFhi and BATFlo 
LZ fractions expressed similar levels of Foxo1, assessed by in-
tracellular cytometric analysis (Fig. 7 G).
Next, to address the function of BATF in GC main-
tenance, we used the experimental protocol depicted in 
Fig.  8 A; both Batff/f ERT2cre B1-8hi and Batf+/+ ERT2cre 
B1-8hi B cells were co-transferred into congenically marked 
mice, which were immunized with NP-CGG, and then 
treated with tamoxifen to delete Batf in GC B cells (Fig. 8 D). 
As shown in Fig. 8 B, in contrast to control vehicle treatment, 
tamoxifen injection resulted in a selective decrease of Batff/f 
ERT2cre B1-8hi GC B cells; the decrease was more promi-
nent in the DZ. Furthermore, when EdU was incorporated 
over 0.5 h, BATF-deficient LZ GC B cells showed less pro-
liferation than control cells (Fig.  8  C). Thus, BATF is up- 
regulated by T cell help in a Foxo1-dependent manner, and is 
required for GC B cell proliferation.
The aforementioned findings raise the question of 
whether Foxo1 ablation-mediated anomalies could be ex-
plained by the defective expression of BATF. To explore this 
question, we used a retroviral transduction system, allowing 
for both inducible expression of BATF and inducible dele-
tion of endogenous Foxo1 (Fig.  8  E). Retrovirus-infected 
donor B cells were transferred into congenically marked 
mice, which were immunized and then treated with tamox-
ifen. Transduction with BATF was monitored by GFP, and 
deletion of Foxo1 in Foxo1f/f donor B cells was confirmed 
by RT-qPCR (unpublished data). Foxo1-proficient cells 
transduced by BATF exhibited not significant expansion of 
Figure 4. Gc phenotype with Foxo1 ablation 
during a polyclonal immune response. (A) Sche-
matic representation of the experimental protocol. 
Because entering the GC in the polyclonal stimula-
tion was a little earlier than the monoclonal condition 
(Fig. 2 A), we treated mice with tamoxifen on day 6, 
7, and 8, and analyzed on day 11. (B, top) Flow cy-
tometry of donor B cells (B220+CD45.1−CD45.2+ and 
B220+CD45.1+CD45.2−). (bottom left) Percentage of 
each donor in total donor GC B cells (CD45.1−CD45.2+ 
or CD45.1+CD45.2−B220+GL7+CD38−). (bottom right) 
Ratio of DZ:LZ cells. n = 5 biological replicates. Error 
bars represent SD. *, P < 0.05; ***, P < 0.001; paired 











Figure 5. decreased antigen presentation of Foxo1-deficient LZ Gc B cells. (A, left) Flow cytometry of surface molecules on Foxo1+/+ and Foxo1f/f LZ GC B cells. 
Mice were immunized as described in Fig. 2 A, and LZ GC B cells were prepared on day 12. (right) Histograms indicating the gMFI of each population. n = 3 biological 
replicates. (B) In vitro antigen presentation assay. Mice were prepared as described in Fig. 3 A. Purified splenic B cells were incubated with NP-Eα-GFP or Eα-GFP for 
1 h at 37°C. Antigen-presenting LZ GC B cells were detected by staining the LZ GC B cells (CD45.1+CD138−GL7+CD38−CD86hiCXCR4lo) with Y-Ae antibody. (left) Flow 
cytometry of LZ GC B cells; (middle) the percentage of Y-Ae+ (bracketed line in the left) LZ GC B cells; (right) the gMFI of Y-Ae of Y-Ae+ LZ GC B cells. n = 3 biological 
replicates. (C) In vitro antigen presentation of Foxo1-deficient LZ GC B cells using αDEC-Eα-GFP. Eα-GFP and αDEC-OVA were used as negative controls. Mice were 
prepared as described in Fig. 3 A. (left) Flow cytometry of LZ GC B cells; (right) the percentage of Y-Ae+ (bracketed line in the left) LZ GC B cells. n = 3 biological repli-
cates. (D) Effects of Foxo1 ablation in LZ GC B cells on TFH cell number and cytokine production. (left) Schematic representation of the experimental protocol. Foxo1+/+ 
ERT2cre B1-8hi CD45.1+CD45.2+ or Foxo1f/f ERT2cre B1-8hi CD45.1+CD45.2+ B cells were co-transferred together with CD4+ T cells from OT-II CD45.1+CD45.2+ mice into 
wild-type mice (CD45.1−CD45.2+), which were immunized with NP-OVA/alum i.p. on day 0. Mice were administered tamoxifen p.o. on day 7, 8, and 9, and analyzed on 
day 12. (middle) Flow cytometry of OT-II CD4+ T cells (CD45.1+CD4+). (right) The percentage of TFH cells (CD45.1+CD4+CXCR5+PD-1+) among total donor OT-II cells, and 
the quantification of Il21 mRNA expression in sorted TFH cells by real-time qPCR. n = 8 biological replicates. Error bars represent SD. Data are representative of three 
(A) or two (B–D) independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001; unpaired Student’s t test.
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Figure 6. Foxo1-deficient Gc B cells have defects in proliferation and sHM. (A, top) Schematic representation of the experimental protocol. Mice 
were injected i.p. with αDEC-OVA on day 10 and analyzed on day 12. Bottom, proliferation status of Foxo1+/+ and Foxo1f/f GC B cells assessed by EdU incor-
poration 30 min after an EdU injection. n = 4 biological replicates. (B) JH4 intron SHM analysis in control and Foxo1-deficient LZ GC B cells. (top) Schematic 
representation of the experimental protocol. Bottom left, the pie charts showing the relative frequency of sequences with 0–5 mutations from mice of each 
genotype. n = number of sequences analyzed. (bottom right) Mutation frequencies (number of mutations in a JH4 570 bp intronic region). Red bars indicate 
the mean. (C, left) Expression of selected SHM-related genes in Foxo1+/+ LZ, Foxo1f/f GC, and Foxo1+/+ DZ B cells based on RNA-seq analysis. Relative frag-
ments per kilobase of exon per million reads (FPKM) values normalized with Foxo1+/+ LZ cells are shown. For Dnase1, the FPKM value of Foxo1f/f GC B cells 
was set as 1. #, undetected. n = 3 biological replicates. (right) Flow cytometry of intracellular AID protein expression in Foxo1+/+ LZ, Foxo1f/f GC, and Foxo1+/+ 
DZ GC B cells. Gray histogram, control signal in Aicda KO GC B cells, which were prepared from immunized Aicdaf/f ERT2cre mice treated with tamoxifen. 
Error bars represent SD. Data are representative of two independent experiments (A and C, right), pooled from two independent animals (B), and from one 
experiment with three biological replicates (C, left). *, P < 0.05; paired Student’s t test (A) and Mann-Whitney test (B).
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GC B cells, suggesting that, in these proficient conditions, 
BATF is not a limiting factor. Foxo1-deficient cells trans-
duced by empty retrovirus manifested the expansion defect, 
as expected, whereas this defect was restored by transduction 
of BATF, suggesting that BATF is critical for the effects of 
Foxo1 on GC proliferation (Fig.  8 F). Nevertheless, Foxo1 
ablation-induced polarization defect could not be restored, 
consistent with the previous data that CXCR4 is a direct tar-
get of Foxo1 (Dubrovska et al., 2012; Dominguez-Sola et al., 
2015). Thus, the LZ-dominant phenotype induced by BATF 
ablation (Fig. 8 B) is likely a result of secondary effects caused 
by proliferation anomalies, but not by direct down-regulation 
of CXCR4 as observed in Foxo1 ablation.
Foxo1 acts in a context-dependent manner
The aforementioned results raised the question of why Foxo1 
ablation leads to opposite proliferation outcomes, depending 
on whether it occurs in the preGC or GC stage (Fig. 1 C 
and 2 B). To gain insight into this point, we performed 
BATF deletion experiments at the preGC stage. Expansion 
of BATF-deficient B1-8hi B cells was significantly decreased 
after tamoxifen treatment (Fig. 9 A), similar to what was ob-
served with BATF deletion at the GC phase. However, effects 
of Foxo1 deletion on BATF expression differs between the 
preGC and GC stages. As shown in Fig. 9 B, in preGC B cells 
BATF was up-regulated in Foxo1-deficient B1-8hi B cells. 
A straightforward explanation of these results is that the 
mechanisms by which Foxo1 regulates BATF differ between 
preGC (inhibitory) and GC (stimulatory) phases, although 
the role of BATF in B cell proliferation is similar between 
Figure 7. t cell help triggers BAtF expression in a Foxo1-depen-
dent manner. (A) Expression of selected transcription factors in Foxo1+/+ 
LZ, Foxo1f/f GC, and Foxo1+/+ DZ B cells based on RNA-seq analysis. Rela-
tive FPKM values normalized with Foxo1+/+ LZ cells are shown. (B) Real- 
time qPCR analysis of Batf mRNA in control and Foxo1-deficient LZ GC 
B cells after injection of anti–DEC-OVA. Data were normalized with control 
cells treated with anti–DEC-CS. n = 3 biological replicates. (C) Real-time 
qPCR analysis of Batf mRNA in wild-type LZ GC B cells after injection of 
anti-CD40L. n = 4 biological replicates. (D, left) Flow cytometry of intracel-
lular BATF protein expression in LZ and DZ GC B cells. Gray histogram, con-
trol signal in Batf KO cells prepared as described in Fig. 8 A. Bracketed lines 
indicate the BATFlo and BATFhi populations. (middle left) BATF gMFI of each 
population. n = 3 biological replicates. (middle right) Percentage of BATFhi 
population. n = 3 biological replicates. (right) Percentage of BATFhi popula-
tion in the LZ B cells. B1-8hi CD45.1+ B cells were transferred into wild-type 
mice (CD45.1−CD45.2+), which were immunized with NP-OVA/alum i.p. on 
day 0. Mice were injected i.p. with anti–DEC-OVA or anti–DEC-CS on day 
10. CD45.1+B220+NP+ LZ B cells were analyzed 24 h after injection of each 
antibody. n = 3 biological replicates. (E, left) Cell cycle analysis of BATFlo 
LZ, BATFhi LZ, and DZ GC B cells. (right) The percentage of GC B cells at 
different stages of the cell cycle. S, EdU+ 7-AADint; G2/M, EdU− 7-AADhi; 
G0/G1, EdU− 7-AADlo. Wild-type mice were immunized with NP-CGG/alum 
i.p., followed by injection of EdU on day 10, 30 min before analysis of the LZ 
(B220+GL7+CD38−CD86hiCXCR4lo), and DZ (B220+GL7+CD38−CD86loCXCR4hi) GC 
B cells. n = 5 biological replicates. (F, left) Flow cytometry of intracellular 
BATF and c-Myc-GFP expression in GC B cells of c-Myc-GFP and wild-type 
mice. (right) Percentage of c-Myc-GFP+ populations in BATFhi and BATFlo 
LZ B cells of c-Myc-GFP mice and total LZ B cells of wild-type B cells. n 
= 3 biological replicates. (G) Flow cytometry of intracellular Foxo1 pro-
tein expression in BATFhi and BATFlo LZ GC B cells. Gray histogram, control 
signal in Foxo1 KO LZ B cells. Error bars represent SD. Data are from one 
experiment with three biological replicates (A), or representative of two 
independent experiments (B–G). *, P < 0.05; **, P < 0.01; ***, P < 0.001; 
unpaired Student’s t test.
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these two phases. Hence, our data suggest that the regulatory 
network operating through Foxo1 is highly context-specific.
dIscussIon
By focusing on Foxo1 functions in GC B cells, we demon-
strate that Foxo1 participates in two consecutive processes oc-
curring in the LZ, antigen presentation to GC TFH cells and 
subsequent activation through T cell help, and that through 
these mechanisms Foxo1 regulates the GC B cell proliferation 
program. The latter conclusion is seemingly inconsistent with 
previous studies demonstrating apparently normal expansion 
of Foxo1-deficient GC B cells (Dominguez-Sola et al., 2015; 
Sander et al., 2015). By ablating Foxo1 before or after GC 
establishment, we found that, in contrast to ablation at the 
GC stage, hyper-expansion of preGC B cells was induced by 
Foxo1 deletion at the preGC stage. Therefore, considering 
that class-switching begins at the preGC stage (Toellner et al., 
1998; Shlomchik and Weisel, 2012), it is likely that the previ-
ous studies using a Cγ1-cre have led to deletion of Foxo1 in 
preGC cells, at least to some extents. The observed phenotype 
would thus result from a combination of effects of Foxo1 
deletion at preGC and GC cell stages.
GC B cells expressing higher amounts of surface pM-
HC-II have been thought to receive better quality/quantity 
of help from GC TFH cells, thereby contributing to their pref-
erential proliferation. Indeed, it was shown that B cells de-
ficient in the MHC family molecule H2-O, an inhibitor of 
peptide loading into MHC-II, outcompete H2-O–sufficient 
B cells in mixed knockout and wild-type GCs, even under 
conditions in which BCR affinity for NP was equalized 
(Draghi and Denzin, 2010). Conversely, Foxo1-deficient GC 
B cells with lower levels of surface pMHC-II were less ca-
pable of activating cognate GC TFH cells. This could be most 
likely caused by down expression of BCR in the absence 
of Foxo1. Supporting this possibility, we found that when a 
T cell antigen was targeted to DEC205, instead of BCR, on 
GC B cells, similar surface pMHC-II presentation was in-
duced between mutant and control GC cells.
How does Foxo1 contribute to proper BCR expression 
by LZ GC B cells? Because IgH, and Igα, but not Igβ are ex-
pressed to the same extents at the protein level in Foxo1-de-
ficient LZ GC B cells as in controls (unpublished data), the 
lower level of Igβ is most likely responsible for the lower 
BCR levels on the surface of mutant LZ GC B cells. Indeed, 
in developing B cells, the importance of Igβ for the assem-
bly and the cell surface expression of the preBCR has been 
documented (Gong and Nussenzweig, 1996; Kurosaki, 2002). 
The protein, but not mRNA, level of Igβ was decreased in 
Foxo1-deficient GC cells (unpublished data). In this regard, 
Itch, one of the HECT family of E3 ligases, was reported to 
mediate the constitutive ubiquitinylation of Igβ, and that this 
was required for normal sorting through the endocytic path-
way (Zhang et al., 2007). Hence, one possibility is that such 
ubiquitin-mediated mechanisms might control constitutive 
Igβ protein levels in a Foxo1-dependent manner.
By taking a strategy of providing T cell help by tar-
geting a T cell antigen to GC B cells through DEC205, we 
could show that even after receipt of sufficient T cell help, 
Foxo1-deficient GC B cells cannot induce the normal pro-
liferation program. Thus, in in vivo physiological settings, 
the malfunctioning DZ program in the Foxo1-deficient 
LZ GC cells is likely to result from two defects, the mutant 
B cells receive weaker help from GC TFH cells and are less 
capable of responding to it. Therefore, our data are consis-
tent with a model in which T cell help plays a critical role 
in the LZ-to-DZ switch.
The DZ is believed to be tightly linked with the cell 
cycle; indeed, expression of cell cycle–related genes is in-
creased in the DZ (Victora et al., 2012). Here, B cells in GCs 
devoid of the DZ as a result of the absence of Foxo1 manifest 
three features; 1) defective proliferation; 2) insufficient eleva-
tion of many cell cycle-related genes; and 3) defective induc-
tion of c-Myc and BATF, critical regulators for inducing the 
cell cycle progression. Because CXCR4 is a target of Foxo1, 
Foxo1 controls both access to the anatomical DZ and the 
proliferation program, possibly making it the key coupling 
molecule between these two DZ functions.
As expected because of defective GC B cell prolifer-
ation and defective expression of key enzymes involved in 
SHM, SHM is also perturbed in the absence of Foxo1. SHM 
and selection are thought to take place in distinct zones, 
the DZ and LZ, respectively. This spatial separation has also 
been suggested to be important for normal SHM, because 
GC B cells deficient in CXCR4 displayed defective SHM, 
despite apparently normal cell division. Hence, in the case 
of Foxo1-deficient GC B cells, in addition to the aforemen-
tioned defect, the inability to physically separate sites of SHM 
and selection might also contribute to defective SHM.
Figure 8. BAtF is required for Gc maintenance. (A) Schematic illustration of the experimental protocol for B–D. (B, top) Flow cytometry of NP-specific 
donor B cells (CD45.2+B220+NP+). (bottom left) Histograms showing the donor GC B cell (CD45.2+B220+NP+Fas+CD38−) number in 106 splenocytes. (bottom 
right) The ratio of DZ:LZ cells. n = 4 biological replicates. (C) Proliferation status of Batf+/+ and Batff/f LZ GC B cells assessed by EdU incorporation 30 min 
after an EdU injection. n = 4 biological replicates. (D) Real-time qPCR analysis of Batf mRNA expression in Batf+/+ERT2cre B1-8hi and Batff/f ERT2cre B1-8hi 
GC B cells. n = 4 biological replicates. (E) Schematic illustration of the experimental protocol for F. Note that viral infection efficiencies were comparable 
between samples as assessed by GFP+ population (∼15–20%) before transfer. (F, left) Flow cytometry of CD45.1+B220+ cells. (right) Histograms showing the 
number of GFP+ GC B cell (CD45.1+B220+GFP+CD38−) in 106 splenocytes. n = 8 (Foxo1+/+) and 10 (Foxo1f/f) biological replicates. Error bars represent SD. Data 
are representative of two independent experiments (B and C), from one experiments with three biological replicates (D), representative of four independent 
experiments (F, left), and are pooled from four independent experiments (F, right). *, P < 0.05; **, P < 0.01; ***, P < 0.001; paired Student’s t test (B and C) 
and unpaired Student’s t test (D and F).
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BATF belongs to the AP-1 family of transcription 
factors that include Fos, Jun, and Atf (Dorsey et al., 1995). 
A previous study demonstrates that BATF is required for 
GCs (defined by GL7+Fas+ B cells in this study) in a T cell– 
but not B cell–dependent manner (Ise et al., 2011). CD38, 
rather than Fas, is a better marker to delineate these cells. 
Indeed, both GL7+CD38+ (intermediate cells toward ma-
ture GL7+CD38− GCs) and GL7+CD38− cells express FAS 
to the same extents (Taylor et al., 2012). Here, by using the 
GL7+CD38− marker, we showed the requirement for B cell–
dependent BATF in mature GCs; BATF-deficient B cells, 
when singly transferred, gave rise to GL7+CD38+, but not 
GL7+CD38− GCs (unpublished data). Thus, it is likely that most 
of the GL7+Fas+ B cells detected by the previous study could 
correspond to GL7+CD38+ cells.
As observed in the previous study (Dominguez-Sola et 
al., 2015), we also found that BATF expression is severely re-
duced in Foxo1-deficient LZ GC B cells. An additional three 
lines of evidence allow us to conclude that the GC prolifer-
ation defect seen in the absence of Foxo1 is due, at least in 
part, to defective up-regulation of BATF. First, BATF is up- 
regulated by enforced T cell help in a Foxo1-dependent 
manner. Second, ablation of BATF during the GC reaction, 
like Foxo1 ablation, led to proliferation defect. Finally, forced 
expression of BATF restores the defective GC expansion 
induced by Foxo1 ablation. Because BATF lacks a transcrip-
tional activation domain, it acts through its interactions with 
other Jun or IRF family members (Murphy et al., 2013). 
Probably, not appreciably increase in the GC expansion by 
overexpression of BATF in Foxo1-proficient cells could be 
explained by requirement for other partners to exert the 
BATF action. Despite the importance of BATF, it is clearly 
only one of several critical factors underlying the defective 
proliferation induced by Foxo1 ablation. For instance, incom-
plete up-regulation of c-Myc in the absence of Foxo1 also 
appears to contribute to.
In regard to regulation of BATF by Foxo1, no signifi-
cant binding of Foxo1 to Batf locus was observed in human 
GC B cells in a previous ChIP-seq analysis (Dominguez-Sola 
et al., 2015). Instead, our gene set enrichment analysis showed 
that Foxo1-deficient LZ GC B cells were more weakly im-
printed by BCR and CD40 signature genes, simply suggest-
ing the involvement of Foxo1 in BCR and CD40 signaling. 
Moreover, BATFhi expression is restricted to a small fraction 
Figure 9. BAtF is required for preGc B cell expansion and is up-regulated in Foxo1-deficient preGc B cells. (A, top) Schematic illustration of the 
experimental protocol. Batf+/+ ERT2cre B1-8hi (CD45.1+CD45.2+) and Batff/f ERT2cre B1-8hi (CD45.1−CD45.2+) B cells were co-transferred into recipient mice 
(CD45.1+CD45.2−), which were immunized with NP-CGG/alum i.p. on day 0. Mice were administered tamoxifen or vehicle p.o. for 3 d and analyzed on day 
4. (bottom left) Flow cytometry of NP-specific donor B cells (CD45.2+B220+NP+). (bottom right) Histograms showing the cell number of total donor cells 
(CD45.2+NP+B220+) and early GC B cells (CD45.2+NP+B220+GL7+CD38−) in 106 splenocytes. n = 4 biological replicates. (B) Real-time qPCR analysis of Batf 
mRNA expression in control and Foxo1-deficient B1-8hi preGC (donor B220+NP+CD38+GL7+) and LZ GC B cells (donor B220+NP+GL7+CD38−CD86hiCXCR4lo). 
preGC B cells and LZ GC B cells were prepared from mice as described in Fig. 1 C and Fig. 2 A, respectively. n = 3 biological replicates. Error bars represent 
SD. Data are representative of three (A) or two independent experiments (B). *, P < 0.05; **, P < 0.01; ***, P < 0.001; paired Student’s t test (A) and un-
paired Student’s t test (B).
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of LZ GC B cells, which also express c-Myc. The c-Myc+ 
GC B cell fraction has been reported to be enriched for high 
affinity BCRs, which are required for strong T cell help. Tak-
ing these observations together, we speculate that, rather than 
direct transcriptional regulation of BATF by Foxo1, Foxo1 
is required for generating strong BCR and CD40 signaling 
by modulating the expression of such receptors, associated 
signaling molecules, and/or transcriptional regulators, which 
in turn, leads to up-regulation of BATF.
Considering the previous conventional idea that Foxo1 
acts as a tumor suppressor, it has been puzzling why GC- 
derived diffuse large B cell lymphomas frequently carry mu-
tations in Foxo1 that prevent its inactivation by Akt (Trinh et 
al., 2013). A large number of Foxo1-bound sites was reported 
to co-localize with sites bound by Bcl6, suggesting that Foxo1 
and Bcl6 cooperate in the transcriptional modulation of a 
subset of targets (Dominguez-Sola et al., 2015). Such modu-
lation of Foxo1 activity by Bcl6 likely makes Foxo1 exert an 
unconventional proliferative role specifically in GC B cells, 
providing an explanation for the generation of GC-derived 
lymphomas by active Foxo1.
MAterIALs And MetHods
Mice
Foxo1f/f (Paik et al., 2007), B1-8hi (Shih et al., 2002), c-Myc-
GFP (Huang et al., 2008), and Cd19cre/+ (Rickert et al., 1997) 
mice were provided by R.A. DePinho (The University of Texas 
MD Anderson Cancer Center, Houston, TX), M.C. Nussenz-
weig (Tha Rockefeller University, New York, NY), B.P. Sleck-
man (Washington University School of Medicine, St. Louis, 
MO), and K. Rajewsky (Max Delbruck Center for Molecular 
Medicine in the Helmholtz Alliance, Berlin-Buch, Germany), 
respectively. Rosa26-ERT2cre mice were obtained from 
Taconic Farms. Il21+/− and OT-II mice were obtained from The 
Jackson Laboratory. Batff/f (Kuwahara et al., 2016) and μMT 
(Kitamura et al., 1991) mice were described previously. Aic-
daf/f mice were generated by homologous recombination using 
Bruce4 ES cells so that exons 2 and 3 were flanked with two 
loxp sites. Positive ES clones were used for microinjection to 
obtain chimeric mice, which were then crossed with C57BL/6 
mice to obtain germline transmitted animals. C57BL/6 mice 
were purchased from CLEA Japan. Sex-matched 8–15-wk-old 
mice were used for all the experiments. For the experiments 
with mixed bone marrow chimeras, C57BL/6 mice were le-
thally irradiated (8.5 Gy) and reconstituted with a mixed inoc-
ulum of 80% μMT and 20% Il21+/− bone marrow cells at least 
8 wk before immunization. All mice were bred and maintained 
under specific pathogen–free conditions and all animal experi-
ments were performed under the institutional guidelines of the 
Institute of Physical and Chemical Research Research Insti-
tute, Osaka University, and Washington University in St. Louis.
Immunization
Mice were immunized with 100 µg of NP-CGG or NP-
OVA precipitated with Imject alum (Thermo Fisher Scien-
tific), or with ∼5 × 108 SRBCs by i.p. injection. The deletion 
of the loxP-flanked allele of the target genes was induced by 
oral administration (p.o.) of 2 mg tamoxifen (Sigma-Aldrich) 
in sunflower oil (Sigma-Aldrich) once per day for 3 d.
Flow cytometry analysis
Single-cell suspensions of splenocytes were prepared and an-
alyzed as previously described (Inoue et al., 2015). Anti-B220 
(RA3-6B2), IgG1 (A85-1), CD138 (281–2), CD45.2 (104), 
IgM[a] (DS-1), PD-1 (J43), CXCR5 (2G8), CD19 (1D3), and 
Fas (Jo2) were purchased from BD. Anti-GL7 (GL7), CXCR4 
(2B11), CD4 (GK1.5), Igα (HM47), MHC-II (M5/114.15.2), 
CD16/32 (93), ICO SL (HK5.3), CD80 (16-10A1), IgD (11-
26c), and AID (mAID-2) were purchased from eBioscience. 
Anti-CD38 (90), CD86 (GL-1), CD45.1 (A20), Igβ (HM79-
12), CD22 (OX-97), CD40 (3/23), CD83 (Michel-19), 
CCR6 (29-2L17), and Brilliant Violet 510 Streptavidin were 
purchased from BioLegend. For staining with an isotype 
control for CD86 (Fig. 4 C), we used anti-CD83 instead of 
anti-CD86 for gating LZ GC B cells. For intracellular stain-
ing, the cells were fixed and permeabilized using a Foxp3 
staining kit (eBioscience) for anti-Foxo1 (C29H4; Cell Sig-
naling Technology) staining, or a True-Nuclear Transcrip-
tion Factor Buffer Set (BioLegend) for anti-BATF (D7C5; 
Cell Signaling Technology) staining. Cells were incubated 
with first antibody, and then incubated with Alexa Fluor 
488– or Alexa Fluor 647–conjugated anti–rabbit antibody 
(Thermo Fisher Scientific). APC-conjugated NP was pre-
pared as described previously (Shinnakasu et al., 2016). For 
EdU incorporation assays, mice were injected i.p. with 1 mg 
EdU (Thermo Fisher Scientific) in PBS and sacrificed 30 
min later. Splenocytes were surface-stained, and then EdU- 
incorporated cells were identified using a Click-iT Plus EdU 
Flow Cytometry Assay kit (Thermo Fisher Scientific) accord-
ing to the manufacturer’s instructions.
Adoptive transfers
Adoptive transfer experiments were performed as described 
previously (Shinnakasu et al., 2016). In brief, splenic B cells 
were purified by magnetic cell depletion using anti-CD43 
MicroBeads and the AutoMACS system (Miltenyi Bio-
tec). For B1-8hi B cell transfer experiments, purified B1-8hi 
B cells containing 105 NP-binders (a 1:1 mixture of 5 × 104 
NP-binders for co-transfer experiments) were transferred 
i.v. into recipient mice. For B cell co-transfer experiments in 
Figs. 4 and 6 B, 107 purified B cells (a 1:1 mixture of 5 × 106 
B cells) were used for donor.
sHM sequence analysis of the JH4 intron
Mice were co-transferred with Foxo1+/+ ERT2cre 
(CD45.1+CD45.2–) and Foxo1f/f ERT2cre (CD45.1+CD45.2+) 
B cells, and immunized with NP-CGG/alum on day 0. On 
day 7, 8, and 9, mice were orally administered tamoxifen. On 
day 14, LZ GC B cells from each donor were sorted (∼103 
cells) for genomic DNA purification. JH4 intron sequences 
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were amplified using Ex Taq DNA polymerase (Takara 
Bio Inc.) with primers 5′-TCC TAG GAA CCA ACT TAA 
GAGT-3′ and 5′-TGG AGT TTT CTG AGC ATT GCAG-
3′ (Gitlin et al., 2014). PCR products were subcloned into 
the pGEM-T vector (Promega) and single clones (∼50 
per mouse) were sequenced.
In vitro antigen presentation assay
Purified splenic B cells (∼2.5 × 106 cells) were incubated 
with 1 µg/ml NP-Eα-GFP, Eα-GFP (Itano et al., 2003; 
Pape et al., 2007), αDEC-OVA (Boscardin et al., 2006), or 
αDEC-Eα-GFP for 1 h at 37°C. Surface pMHC-II was de-
tected by staining the NP-specific LZ GC B cells with bio-
tin-conjugated Y-Ae antibody (eBioscience). For generation 
of αDEC-Eα-GFP, cDNA encoding Eα-GFP was inserted 
in frame with the carboxyl terminus of the heavy chain of 
mouse αDEC-205 (Boscardin et al., 2006), and the fusion 
antibody was expressed using Expi293 Expression System 
(Thermo Fisher Scientific) and purified on HiTrap Protein G 
HP column (GE Healthcare).
rnA-seq analysis
Wild-type mice were co-transferred with Foxo1+/+ ERT2cre 
B1-8hi (CD45.1+CD45.2−) and Foxo1f/f ERT2cre B1-8hi 
(CD45.1+CD45.2+) B cells, and immunized with NP-CGG 
precipitated in alum on day 0. On day 7, 8, and 9, mice 
were orally administered tamoxifen. On day 12, Foxo1+/+ 
LZ (CD45.1+CD45.2−B220+NP+GL7+CD38−CD86hiCX-
CR4lo) and DZ GC B cells (CD45.1+CD45.2–B220+N-
P+GL7+CD38−CD86loCXCR4hi), and Foxo1f/f GC B cells 
(CD45.1+CD45.2−B220+NP+GL7+CD38−) were sorted for 
RNA preparation. Three biological replicates were used in 
each genotype. Construction of DNA libraries for RNA-
seq and sequencing were performed as described previously 
(Shinnakasu et al., 2016). In brief, the DNA library was con-
structed using an NEBNext Ultra RNA Library Prep kit for 
Illumina (NEB) from total RNA purified from ∼104 sorted 
cells. RNA-sequencing was performed on a HiSeq 1500 se-
quencer (Illumina) in a 49-bp single-end read mode. Gene 
set enrichment analysis was performed using GSEA software 
v2.2.2 (Subramanian et al., 2005). The lists of gene signature 
of up-regulated genes by CD40 and BCR stimulation for 
gene set enrichment analysis were previously described (Vic-
tora et al., 2010; Shinnakasu et al., 2016). The RNA-seq data 
are available at Gene Expression Omnibus database under 
accession no. GSE93554.
Anti–dec-oVA and anti-cd40L treatment
For anti–DEC-OVA treatment, wild-type mice were co-trans-
ferred with Foxo1+/+ ERT2cre B1-8hi (CD45.1+CD45.2−) 
and Foxo1f/f ERT2cre B1-8hi (CD45.1+CD45.2+) B cells, and 
immunized with NP-OVA precipitated in alum on day 0. 
On day 7, 8, and 9, mice were orally administered tamoxi-
fen. The mice were injected i.p. with 10 µg anti–DEC-OVA 
(Victora et al., 2010) on day 10, and sacrificed for analysis on 
day 12. As a control, we used a chimeric antibody in which 
anti-DEC205 was fused to an irrelevant antigen, Plasmodium 
falciparum circumsporozoite protein (anti–DEC-CS). For 
anti-CD40L treatment, wild-type mice were immunized i.p. 
with NP-CGG in alum on day 0. The mice were injected i.p. 
with 250 µg IgG1 anti-CD40L (MR1; Bio X Cell) or control 
hamster IgG (Innovative Research) on day 7 and sacrificed 
for analysis 12 h later.
Immunohistochemistry
Spleens were fixed in 4% paraformaldehyde for 2 h on ice, 
and then incubated in PBS overnight at 4°C. Next, the 
spleens were embedded in Tissue-Tek OCT Compound 
(Sakura Finetek) and frozen at –80°C. 8-µm-thick sections 
were mounted on glass slides and blocked with CAS-Block 
(Invitrogen) for 10 min at room temperature. The samples 
were first stained with biotin anti-CD45.1, followed by in-
cubation with Alexa Fluor 546 streptavidin (Thermo Fisher 
Scientific), eFluor 450 anti-IgD (11-26c; eBioscience), and 
APC anti-CD21/35 (7G6; BD). Images were acquired using 
a Fluoview FV10i confocal microscope system (Olympus). 
CD45.1 signal intensity was quantified using ImageJ software 
(National Institutes of Health), by which relative mean inten-
sity values of CD45.1 signals in the DZ compared with those 
in the LZ was calculated.
Western blot
Sample preparation and Western blot were performed as de-
scribed previously (Inoue et al., 2015). Immunoblotting was 
performed using anti-Foxo1 (C29H4; Cell Signaling Technol-
ogy) and anti–β-actin (C-11; Santa Cruz Biotechnology, Inc.).
qPcr analysis
Real-time qPCR was performed as described previously (Inoue 
et al., 2015). Actb mRNA levels were used for normalization. 
The following primers were used for qPCR analysis: Foxo1 
forward, 5′-AAG AGC GTG CCC TAC TTC AA-3′; Foxo1 re-
verse, 5′-CTG TTG TTG TCC ATG GAC GC-3′; Foxo3 for-
ward, 5′-AGG ATA AGG GCG ACA GCA AC-3′; Foxo3 reverse, 
5′-CCC GTG CCT TCA TTC TGA-3′; Foxo4 forward, 5′-CTT 
CCT CGA CCA GAC CTCG-3′; Foxo4 reverse, 5′-ACA GGA 
TCG GTT CGG AGT GT-3′; Il21 forward, 5′-TCA GCT CCA 
CAA GAT GTA AAG GG-3′; Il21 reverse, 5′-GGG CCA CGA 
GGT CAA TGAT-3′; Batf forward, 5′-GTT CTG TTT CTC 
CAG GTCC-3′; Batf reverse, 5′-GAA GAA TCG CAT CGC 
TGC-3′; Actb forward, 5′-CCG CCA CCA GTT CGC CATG-
3′; Actb reverse, 5′-TAC AGC CCG GGG AGC ATC GT-3′.
Inducible retroviral expression of BAtF in vivo
To inducibly express BATF in Foxo1-deficient B cells in 
vivo, Foxo1+/+ ERT2cre B1-8hi (CD45.1+CD45.2+) or Fox-
o1f/f ERT2cre B1-8hi (CD45.1+CD45.2+) mice were immu-
nized i.p. with 50 µg of NP-Ficoll in PBS. 6 h later, splenic 
B cells were purified from these mice and cultured with 2 
µg/ml anti-CD40 for 18 h in vitro. Cells were then retro-
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virally transduced with an inducible BATF expression cas-
sette by spin infection (800 g, 90 min, 25°C) with polybrene 
(8 µg/ml, Millipore) and virus supernatant produced in 
PLAT-E cells. The retroviral vector was constructed by in-
serting loxp-flanked human CD2, mouse BATF cDNA, and 
IRES-EGFP into pMYs vector (Fig.  8 E). 3 h after infec-
tion, 106 B cells were transferred i.v. into CD45.1−CD45.2+ 
wild-type mice, which were immunized i.p. with 100 µg of 
NP-CGG/alum on day 0, followed by tamoxifen injection 
p.o. on day 6, 7, and 8 to induce Foxo1 deletion and BATF 
expression, and analysis on day 15.
statistical analysis
Statistical analyses were performed with a two-tailed un-
paired Student’s t test, a two-tailed paired Student’s t test, or a 
Mann-Whitney test using GraphPad Prism software.
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